Press Releases InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules June 2, 2022 Read More » InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update May 13, 2022 Read More » InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV May 2, 2022 Read More » InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert April 28, 2022 Read More » InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert April 28, 2022 Read More » InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector April 21, 2022 Read More » InMed Announces Management Changes March 17, 2022 Read More » InMed to Present at the 34th Annual Roth Conference March 8, 2022 Read More » InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica February 15, 2022 Read More » InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update February 14, 2022 Read More » InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022 February 10, 2022 Read More » InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector January 19, 2022 Read More » InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook January 5, 2022 Read More » Registration Now Open For Tribe Public’s Webinar Event “Addressing The Increasing Demand For Rare Cannabinoids” Featuring InMed’s Management Team On January 6, 2022 December 30, 2021 Read More » InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma December 20, 2021 Read More » InMed Announces Results of 2021 Annual General Meeting December 17, 2021 Read More » InMed Pharmaceuticals to Participate in Cowen’s 4th Annual Cannabis Conference November 23, 2021 Read More » InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update November 10, 2021 Read More » InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid November 3, 2021 Read More » InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids October 13, 2021 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules June 2, 2022 Read More »
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update May 13, 2022 Read More »
InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV May 2, 2022 Read More »
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert April 28, 2022 Read More »
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert April 28, 2022 Read More »
InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector April 21, 2022 Read More »
InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica February 15, 2022 Read More »
InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update February 14, 2022 Read More »
InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022 February 10, 2022 Read More »
InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector January 19, 2022 Read More »
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook January 5, 2022 Read More »
Registration Now Open For Tribe Public’s Webinar Event “Addressing The Increasing Demand For Rare Cannabinoids” Featuring InMed’s Management Team On January 6, 2022 December 30, 2021 Read More »
InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma December 20, 2021 Read More »
InMed Pharmaceuticals to Participate in Cowen’s 4th Annual Cannabis Conference November 23, 2021 Read More »
InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update November 10, 2021 Read More »
InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid November 3, 2021 Read More »
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids October 13, 2021 Read More »
